779 patents
Page 4 of 39
Utility
ANTI-IL-2 Antibodies and Compositions and Uses Thereof
26 Oct 23
The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ.
Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
Filed: 16 Sep 22
Utility
Bicyclic-Fused Heteroaryl or Aryl Compounds
26 Oct 23
JOHN DAVID TRZUPEK, KATHERINE LIN LEE, MARK EDWARD BUNNAGE, SEUNGIL HAN, DAVID HEPWORTH, FRANK ELDRIDGE LOVERING, JOHN PAUL MATHIAS, NIKOLAOS PAPAIOANNOU, BETSY SUSAN PIERCE, JOSEPH WALTER STROHBACH, STEPHEN WAYNE WRIGHT, CHRISTOPH WOLFGANG ZAPF, LORI KRIM GAVRIN, ARTHUR LEE, DAVID RANDOLPH ANDERSON, KEVIN JOSEPH CURRAN, CHRISTOPH MARTIN DEHNHARDT, EDDINE SAIAH, JOEL ADAM GOLDBERG, XIAOLUN WANG, HORNG-CHIH HUANG, RICHARD VARGAS, MICHAEL DENNIS LOWE, AKSHAY PATNY
Filed: 28 Jun 23
Utility
n786v875nys7rcczkinq4yhdusgtl
26 Oct 23
The present disclosure describes single agent and combination therapies and uses for the treatment of cancer and/or cancer-associated diseases.
Nathalie Annie BARDY BOUXIN, Eloisa Virginia BARRY, John Andrew BLAKE-HASKINS, Geoffrey Wing-Lynn CHAN, Jeffrey CHOU, Mohamed A ELMELIEGY, Heike Iris KRUPKA, Kai Hsin LIAO, Erik Rene VANDENDRIES, Andrea VIQUEIRA, Paul Stephen WISSEL, Anne YVER
Filed: 10 Sep 21
Utility
4orarkiuc81mz3g2sayftcf
26 Oct 23
The present invention relates to compounds that inhibit KRas G12D.
Xiaolun Wang, Matthew Arnold Marx, John David Lawson, Shelley Allen, Patrick Michael Barbour, James Francis Blake, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Sherif Hosam Hassanien, Michael Christopher Hilton, Macedonio Junior Mejia, Jacob Matthew O’Leary, Tony Pisal Tang
Filed: 3 Aug 21
Utility
bpk01zkzauabg8u4rgc9tuxw0gx4ox6a6pcpsnc7fbukp0u
26 Oct 23
The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer.
Chew Shun CHANG, Gurkan GUNTAS, Madan KATRAGADDA, Divya MATHUR, Adam Reid ROOT, Lidia MOSYAK, Edward Roland LAVALLIE
Filed: 27 Oct 22
Utility
4xm3u4 ihqze1r1cjhpkm2ffh8uekoify8h0h6pidb9hu9emuhw8f15e
26 Oct 23
The present invention provides methods of protecting ribonucleic acid (RNA) from degradation under certain conditions by contacting the RNA with compounds that contain at least one boron atom.
Timothy Leyden Foley, Christopher John Helal
Filed: 27 Aug 21
Utility
zedm20j0nj9s45pera34 xk5or9uu8
19 Oct 23
Technology is disclosed for monitoring a user's respirator), condition and provide decision support by analyzing a user's audio data.
Shyamal Patel, Paul William Wacnik, Kara Chappie, Robert Mather, Brian Tracey, Maria del Mar Santamaria Serra
Filed: 30 Aug 21
Utility
7ypmxx1qtzlq5feth4c8luiadb9ldwrf7pe3a
12 Oct 23
Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
Filed: 3 May 23
Utility
vxtcq654kdm7dwapagjdzt6f
12 Oct 23
This invention relates to combination therapies for use in treating cancer, comprising a cyclin dependent kinase 2 (CDK2) inhibitor of Formula (I), as further described herein, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, optionally in further combination with an additional anti-cancer agent=.
Stephen George DANN, Nichol Lee Goodman MILLER, Todd Lee VANARSDALE
Filed: 16 Jul 21
Utility
9hveh0t7uyeps1qszcz2ip2fnrnw ig0fmi
12 Oct 23
The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%.
Annaliesa Sybil Anderson, Robert George Konrad Donald, Julio Cesar Hawkins, Srinivas Kodali, Raphael Simon
Filed: 23 Aug 21
Utility
t90uxyhvx1sy7eayqkvz3kusuv ff4vqi2
10 Oct 23
Ronald Jay Hinklin, Shelley Allen, Patrick Barbour, Adam Cook, Joshua Dahlke, John Gaudino, Ellen Laird, Oren T. McNulty, Qian Zhao
Filed: 15 Jul 21
Utility
6jfyzjh63vdob7bprliunpfpux4758b 2pve133sy2
10 Oct 23
Hui Li, Seiji Nukui, Stephanie Anne Scales, Min Teng, Chunfeng Yin
Filed: 1 Dec 21
Utility
x5n6k k8nhjyeivtscl46f
10 Oct 23
The present invention relates to a polypeptide comprising 7 β-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first α-helix sequentially located on the EF chain between β-strands E and F, wherein the β-strands are arranged so as to form a first β-sheet comprising β-strands A, B, D, and E, and a second β-sheet comprising β-strands C, F and G, said first and second β-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between β-strands E and F comprises the sequence X1-X2-X3-X4-K5H6 (SEQ ID NO:98), and X1, X3 and X4 are each independently any amino acid residue, characterized in that X2 is selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof.
Olivier Alexandre Laurent, Alice Lee, Richard Ryan Preston, David Tumelty, Wei Hong Yu, Abhijit Suresh Bhat, Anna Tempczyk-Russell
Filed: 9 Jun 20
Utility
rbzlaxvqydkdx5fdjfz1xscagi4k9mzjxfh9t9
10 Oct 23
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a histone deacetylase (HDAC) inhibitor.
Emma Linderoth, Natasja Nielsen Viller, Robert Adam Uger, Penka Slavcheva Slavova-Petrova
Filed: 1 Nov 17
Utility
phjxd864wb8e6j1e9cqy1ll7f5aymk70d6xrolwl09lp05vayi2
5 Oct 23
The present invention relates to the discovery of chemically and physically stable topical formulations comprising (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol (PF-07038124) for treating inflammatory disorders and to methods of preparing the topical formulations.
Thean Yeow Yeoh
Filed: 16 Aug 21
Utility
wrxpmi5kmzqh843qdr79z7kn81t9suff9sw1h2nwvsm3nrqr3q9n
3 Oct 23
This patent application relates to the treatment of cancer and other diseases that have a CD47+ phenotype.
Lei Cui, Lisa Danae Schultz Johnson
Filed: 5 Nov 18
Utility
cbi06p5kqjg75kgto124mjma0i7 6vd5gfgrm9atj4klbv1watfk7oggx2t
3 Oct 23
Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
Filed: 20 Apr 21
Utility
z1q17mkos5eb0vgoumxcboph4ju6apsfmv9rm32yn
21 Sep 23
There are methods, dosage regimens, and compositions for treating hidradenitis suppurativa.
Brian Gerstenberger, Andrew Fensome, Dafydd Owen
Filed: 8 Mar 23
Utility
keql97xi44usv mkav0q
14 Sep 23
The invention relates to a purification method of an RSV protein, wherein a load solution comprising the RSV protein is contacted with an anion exchange chromatography medium, whereby the RSV protein binds to the anion exchange chromatography medium, the anion exchange chromatography medium is washed with at least one wash solution and the RSV protein is eluted from the anion exchange chromatography medium.
Jill Ann PADDOCK, Alexandra PETTAWAY, Jeffrey Richard SALM
Filed: 22 Jul 21
Utility
52zc68ylzqrvgcns7q7mlql2z1wv9u04yfq5wdfy8s0o2wexh b9stx
14 Sep 23
Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells.
Yi ZHANG, Thomas John VAN BLARCOM, Siler PANOWSKI, Silvia K. TACHEVA-GRIGOROVA, Barbra Johnson SASU
Filed: 27 Apr 23